Data as of May 22
| -0.17 / -2.19%|
The 10 analysts offering 12-month price forecasts for Trius Therapeutics Inc have a median target of 12.00, with a high estimate of 20.00 and a low estimate of 10.00. The median estimate represents a +57.89% increase from the last price of 7.60.
The current consensus among 10 polled investment analysts is to Buy stock in Trius Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.